CELLINK Q5 2020 Results and MatTek Acquisition

CELLINK LIFE SCIENCES Successful integration of acquired companies dispendix A CELLINK COMPANY cytena A CELLINK COMPANY scienion A CELLINK COMPANY GINOLIS A CELLINK COMPANY • €5 MM in transaction value - 60% in shares / 40% in cash • Part of the bioprinting and drug development screening process • • Cross-sales opportunities and increased customer value with CELLINK Acquired at 11x Revenue, now at ~ 1x revenue. (In 2 years) • • • ~€30 MM in transaction value - 60% in shares / 40% in cash • ~40% EBITDA margin Strengthen position in research workflow and with big pharma (~90% of customer base) Cross-sales opportunities with CELLINK and Dispendix Acquired at ~ 7x Revenue, now at 3-5x revenue. (In 1.5 years) • ~€80 MM in transaction value - 50% / 50% in shares/cash ~25% EBITDA margin Strengthen position in single- cell handling Creating a low volume dispensing powerhouse with Dispendix and a dominant player in single-cell dispensing with Cytena Acquired at ~3.7x Revenue, now at ~2.7x. (In 4 months) ~€70 MM in transaction value - 40% / 60% in shares/cash ~12% EBITDA margin Strengthen position in automation and diagnostics Creating an automation and low-volume dispensing powerhouse with SCIENION and Business area Bioprinting Acquired at ~3.8x Revenue O CELLINK 2021, All rights reserved.

View entire presentation